Third Bridge

Geopulse Exploration, Inc. Acquires 50% of ATC Services

Retrieved on: 
Wednesday, April 10, 2024
Permian, Tears, Blood, Third Bridge, Public, Acquisition, ATC, Perspiration, Growth

ATC Services is headquartered in the Permian Basin of Texas and is engaged in the business of oil and gas construction, maintenance, and fabrication services.

Key Points: 
  • ATC Services is headquartered in the Permian Basin of Texas and is engaged in the business of oil and gas construction, maintenance, and fabrication services.
  • ATC Services provides high-margin support services to some of the largest players in the Permian and provides services including but not limited to drilling and facility pad construction, road construction and maintenance, frac pit construction, pit closures, fabrication, environmental remediation, hydrovacs, vacuum trucks, and other services.
  • In the first closing, which took place on April 9, 2024, Geopulse acquired fifty percent (50%) of the outstanding ATC membership units.
  • ATC Services will operate as a wholly-owned subsidiary of Geopulse after the second closing.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Thursday, March 7, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Third Bridge, ADS, Pomerantz, Cancer, Court, Biotechnology, Person, BioNTech, Omicron, Prior, News, Food, Complaint, District court, Risk, Ext, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Infection, Action Replay, Cost, Research, Pharmaceutical industry

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Wednesday, February 28, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Third Bridge, ADS, Pomerantz, Cancer, Court, Biotechnology, Person, BioNTech, Omicron, News, Food, Complaint, District court, Risk, Ext, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Infection, Action Replay, Cost, Research, Pharmaceutical industry

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIONTECH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 23, 2024
Pfizer–BioNTech COVID-19 vaccine, Third Bridge, ADS, Court, The Company, BioNTech, Omicron, News, Food, Advertising, Risk, Woman, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Cost, Research, Pharmaceutical industry

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $100,000 investing in BioNTech stock or options between March 30, 2022 and October 13, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Tuesday, February 20, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Third Bridge, ADS, Pomerantz, Cancer, Court, Biotechnology, Person, BioNTech, Omicron, Prior, News, Food, Complaint, District court, Risk, Ext, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Infection, Action Replay, Cost, Research, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, February 15, 2024
Pfizer–BioNTech COVID-19 vaccine, Third Bridge, ADS, Court, The Company, BioNTech, Omicron, News, Food, Advertising, Risk, Woman, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Cost, Research, Pharmaceutical industry

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Sunday, February 11, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Third Bridge, ADS, Pomerantz, Cancer, Court, Biotechnology, Person, BioNTech, Omicron, Prior, News, Food, Complaint, District court, Risk, Ext, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Infection, Action Replay, Cost, Research, Pharmaceutical industry

NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, February 8, 2024
Third Bridge, Vaccination, ADS, News, Food, The Company, Advertising, Woman, COVID-19, Pfizer–BioNTech COVID-19 vaccine, Cost, BioNTech, Omicron, EUR, Risk, COVID, LLP, Research, BNTX, Court, Pharmaceutical industry

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Saturday, February 3, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Pomerantz, COVID-19, ADS, Ext, Research, Omicron, News, BNTX, COVID, Biotechnology, BioNTech, District court, Food, Action Replay, Third Bridge, Vaccination, Risk, Complaint, EUR, Infection, LLP, Court, Cancer, Cost, Person, Pharmaceutical industry

NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 2, 2024
Pfizer–BioNTech COVID-19 vaccine, COVID-19, ADS, Research, Advertising, Omicron, News, BNTX, COVID, BioNTech, Food, Third Bridge, Vaccination, Risk, The Company, EUR, Woman, LLP, Court, Cost, Pharmaceutical industry

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).